FDA Recalls & Court Actions: June 20, 1990
Executive Summary
CLASS II -- MUROMONAB-CD3 ORTHOCLONE OKT3 STERILE SOLUTION 5 mg (1 mg/1ml), for IV use only. Lot numbers: 19B007 EXP 11/89, 19D014 EXP 12/89, 68K111 EXP 7/89, 68L116 EXP 8/89, 68N129 EXP 9/89. Manufacturer: Ortho Pharmaceutical Corporation, Biotech Division, Raritan, New Jersey. Recalled by: Manufacturer, by telephone between Aug. 7, 1989 and Dec. 18, 1989. Firm-initiated recall complete. Distribution: Nationwide, Japan, Mexico, Switzerland. Firm estimates none remains on market. Reason: Product failed to maintain stability throughout the approved dating period.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth